Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00759200 | Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients | PHASE2 | COMPLETED | 525 | — | — | Oct 1, 2008 | Dec 1, 2010 | Nov 16, 2016 | 55 | Australia, Canada +10 |
| NCT00724776 | Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients | PHASE1 | COMPLETED | 30 | — | — | Jul 1, 2008 | - | Dec 8, 2020 | 1 | Japan |
| Arm | Type | Description |
|---|---|---|
| alb-interferon arm 1 | EXPERIMENTAL | - |
| alb-interferon arm 2 | EXPERIMENTAL | - |
| alb-interferon arm 3 | EXPERIMENTAL | - |
| alb-interferon arm 4 | EXPERIMENTAL | - |
| peg-interferon | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | Open-label treatment with albinterferon alfa 2b escalating single dose |
| Name | Type | Description |
|---|---|---|
| alb-interferon alfa 2b | DRUG | 900 mcg every 4 weeks |
| peg-interferon | DRUG | Peg-interferon alfa 2a: 180 mcg 1x per wk. |
| Albinterferon alfa 2b | BIOLOGICAL | recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0 |
Inclusion Criteria: * Age of 18 years or older * Clinical diagnosis of chronic hepatitis C * Infection with HCV genotype 2 or 3 * No previous IFNα-based therapy Exclusion Criteria: * Women of child-bearing potential if not using double barrier method of contraception, pregnant or nursing * Fertil...